Webcast CME

 

 

 

 

MDS and MDS/MPN: Past, Present, and Future



Print this Content

How to Obtain AMA PRA Category 1 Credit

  1. Watch the webcast.
  2. Answer the CME polling questions within the webcast.
  3. Log into your myCME account.
  4. Complete the credit and evaluation form.
  5. Print your personalized CME certificate.

Technical Requirements



Release Date:   January 29, 2015
Expiration Date:   January 29, 2017

Estimated Time of Completion:  2 hours, 30 minutes

Description

The MDS and MDS/MPN: Past, Present, and Future webcast features disease research and clinical practice to review the contributions of cytogenetics and molecular genetics to the biology of myelodysplastic syndromes and the overlap disease myelodysplastic syndromes/myeloproliferative neoplasms. Also identified is the role of novel pharmacologic therapies and innovations with transplantation to improve the care of these patient populations.

Learning Objectives

  1. Discuss the natural history, presenting features, and outcomes associated with the various subtypes of MDS/MPN.
  2. Summarize the various cytogenetic techniques used in MDS and MDS/MPN, discuss their strengths and limitations, and analyze their findings.
  3. Discuss the biologic role and clinical importance of newly identified molecular mutations in MDS and MDS/MPN.
  4. Discuss challenges in treatment response criteria and apply data on new and existing pharmacologic therapies for MDS/MPN.
  5. Describe the underlying mechanisms and available options for management of MDS/MPN disease that failed hypomethylating therapy.
  6. Discuss current data on transplant strategies and outcomes in patients with MDS/MPN.

Target Audience

This educational activity is designed for an international audience including medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Cleveland Clinic Foundation and Aplastic Anemia & MDS International Foundation. The Cleveland Clinic Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of  2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Directors and Faculty

Activity Directors

Ramon V. Tiu, MD
Assistant Professor of Molecular Medicine
Department of Translational Hematology and Oncology Research
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Hetty Carraway, MD, MBA
Department of Hematologic Oncology and Blood Disorders
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Faculty

Torsten Haferlach, MD, PhD
MLL Munich Leukemia Laboratory
Munich, Germany

Betty Ky Hamilton, MD
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Elias Jabbour, MD
University of Texas
MD Anderson Cancer Center
Houston, TX

Valeria Santini, MD
University of Florence
Florence, Italy

Francesc Solé, PhD
Institut de Recerca contra la leukemia Josep Carreras
Barcelona, Spain

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:


Hetty Carraway, MD, MBA
  Celgene Independent contractor (including contracted research)
     
     
Torsten Haferlach, MD, PhD
  MLL Munich Leukemia Laboratory Employment, Other – Part Owner
     
     
Ramon V. Tiu, MD
  INCYTE Consulting, Teaching and Speaking

The following faculty have indicated they have no relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

Betty Ky Hamilton, MD
Elias Jabbour, MD
Valeria Santini, MD
Francesc Solé, MD

Acknowledgements

The Cleveland Clinic Foundation Center for Continuing Education acknowledges
educational grants for partial support of this activity from:


Acceleron
Amgen, Inc.
Baxter Healthcare Corporation
Celgene Corporation
CTI BioPharma, Inc.
Geron Corporation
Gilead Sciences, Inc.
MEI Pharma, Inc.
Onconova Therapeutics, Inc.

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education,
Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.